The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10
Open accessAbstract
Limited response to idiotype vaccination in patients with myeloma suggests that there is a need to develop better immunotherapy strategies. It has been determined that the number of high-potency CMRF44+CD14−CD19−dendritic cells (DCs) in the blood of patients with myeloma (range, 0.03%-0.8% of mononuclear cells [MNCs]; n = 26) was not significantly different from that in controls (range, 0.05%-0.8% of MNCs; n = 13). Expression of the costimulatory molecules CD80 and CD86 on DCs from these patients (mean, 29%±17% of MNCs and 85%±10% of MNCs, respectively) was also normal (mean, 29%±17% and 86%±16% of MNCs, respectively). Up-regulation of CD80 expression in response to stimulation by human (hu)CD40LT + interleukin (IL)-2 was significantly reduced on the DCs of patients with myeloma during stable disease (n = 9) and was absent during progressive stages (n = 7) of disease. Similar effects were seen on B cells but not on monocytes of the same group of patients. CD86 expression on DCs was high before (86%) and after (89%) stimulation. Inhibition of CD80 up-regulation was neutralized by either anti–transforming growth factor (TGF)–β1 or anti–IL-10. Up-regulation of CD80 on DCs of controls was inhibited by rTGF-β1 in a dose-dependent manner. Serum TGF-β1 and IL-10 levels were normal in most patients studied. Cytoplasmic TGF-β1 was increased in plasma cells during progressive disease. Thus patients with myeloma have normal numbers of DCs, but CD80 expression may fail to be up-regulated in the presence of huCD40LT because of tumor-derived TGF-β1 or IL-10. Autologous high-potency DCs may have to be tested for CD80 up-regulation and biologically modified ex vivo before idiotype priming for immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dendritic Cells: Unique Leukocyte Populations Which Control the Primary Immune Response
Hart, D. N. J. (1997) · Blood · doi:10.1182/blood.v90.9.3245 · Cited by 1,483
Self-citationInduction of tolerance by IL-10-treated dendritic cells
Steinbrink, K., Wölfl, M., Jonuleit, H., Knop, J., & Enk, A. H. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.10.4772 · Cited by 1,246
Linsley, P. S., Brady, W., Grosmaire, L., Aruffo, A., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.3.721 · Cited by 1,127
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., et al. (1999) · Nature Medicine · doi:10.1038/9525 · Cited by 1,113
Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells.
Groux, H., Bigler, M., de Vries, J. E., & Roncarolo, M. G. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.1.19 · Cited by 777
Ranheim, E. A., & Kipps, T. J. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.4.925 · Cited by 580
Rettig, M. B., Ma, H. J., Vescio, R. A., Põld, M., Schiller, G., Belson, D., Savage, A., Nishikubo, C., Wu, C., Fraser, J., et al. (1997) · Science · doi:10.1126/science.276.5320.1851 · Cited by 458
Reichardt, V. L., Okada, C. Y., Liso, A., Benike, C. J., Stockerl-Goldstein, K. E., Engleman, E. G., Blume, K. G., & Levy, R. (1999) · Blood · doi:10.1182/blood.v93.7.2411 · Cited by 394
Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity
Guinan, E., Gribben, J., Boussiotis, V., Freeman, G., & Nadler, L. (1994) · Blood · doi:10.1182/blood.v84.10.3261.3261 · Cited by 358
Chen, W., Jin, W., & Wahl, S. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.10.1849 · Cited by 352
Cited by
Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
Quach, H., Ritchie, D., Stewart, A. K., Neeson, P., Harrison, S., Smyth, M. J., & Prince, H. M. (2010) · Leukemia · doi:10.1038/leu.2009.236 · Cited by 600
Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel Agents
Nucci, M., & Anaissie, E. (2009) · Clinical Infectious Diseases · doi:10.1086/605664 · Cited by 347
Bone marrow microenvironment and the identification of new targets for myeloma therapy
Podar, K., Chauhan, D., & Anderson, K. C. (2009) · Leukemia · doi:10.1038/leu.2008.259 · Cited by 337
Cohen, N., Mouly, E., Hamdi, H., Maillot, M.-C., Pallardy, M., Godot, V., Capel, F., Balian, A., Naveau, S., Galanaud, P., et al. (2006) · Blood · doi:10.1182/blood-2005-07-2760 · Cited by 170
Hamdi, H., Godot, V., Maillot, M.-C., Prejean, M. V., Cohen, N., Krzysiek, R., Lemoine, F. M., Zou, W., & Emilie, D. (2007) · Blood · doi:10.1182/blood-2006-10-052506 · Cited by 126
Metadata
- Authors
- Brown, R. D., Pope, B., Murray, A., Esdale, W., Sze, D. M., Gibson, J., Ho, P. J., Hart, D., & Joshua, D.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2001-11-15
- Volume
- 98
- Issue
- 10
- Pages
- 2992-2998
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2083426483
- Cited by
- 347
- References
- 25
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10. https://app.cochat.ai/papers/10.1182/blood.v98.10.2992
- The paper
- Brown, R. D., Pope, B., Murray, A., Esdale, W., Sze, D. M., Gibson, J., Ho, P. J., Hart, D., & Joshua, D. (2001). Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10. Blood. https://doi.org/10.1182/blood.v98.10.2992
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
